Setara Biosciences launched with $90 million in funding and a lead program in the clinic targeting Charcot-Marie-Tooth disease type 2C and overactive bladder. The small-molecule asset originated from Actio Biosciences, which was recently acquired by Jazz Pharmaceuticals, linking Setara’s opening franchise to a larger pharma deal pipeline.